Using genetic information for the identification, classification and treatment of Crohn's disease: Are we there yet?

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 6, 2008, Pages 719-721

  Weersma, Rinse K ^a   Wijmenga, Cisca ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; INTERLEUKIN 23; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; INORGANIC PYROPHOSPHATASE; ITPA PROTEIN, HUMAN; METHYLTRANSFERASE; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EDITORIAL; ENTERITIS; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; PHARMACOGENETICS; RISK ASSESSMENT; ALLELE; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR;

ALLELES; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLTRANSFERASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PYROPHOSPHATASES; RISK FACTORS;

EID: 61549100261     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.6.719     Document Type: Editorial

References (11)

1. Pennisi E. Breakthrough of the year. Human genetic variation. Science 318(5858), 1842-1843 (2007).
2. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
3. Odes S, Vardi H, Friger M et al. European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 131, 719-728 (2006).
4. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8, 458-466 (2008).
5. Pimentel M, Chang M, Chow EJ et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am. J. Gastroenterol. 95, 3458-3462 (2000).
6. Weersma RK, Stokkers PCF, van Bodegraven AA et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut DOI 10.1136/gut.2007.144865 (2008).
7. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660-667 (2008).
8. Weersma RK, Peters FT, Oostenbrug LE et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment. Pharmacol. Ther. 20, 843-850 (2004).
9. Dubinsky MC, Reyes E, Ofman J et al. A cost - effectiveness analysis of alternative disease-management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100, 2239-2247 (2005).
10. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J. Gastroenterol. 12, 3657-3667 (2006).
11. Silverberg MS, Satsangi J, Ahmad T et al. An integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19(Suppl. A), 5-36 (2005).